Atara Biotherapeutics Inc (ATRA) Expected to Post Earnings of -$1.15 Per Share

Wall Street brokerages expect Atara Biotherapeutics Inc (NASDAQ:ATRA) to announce ($1.15) earnings per share for the current quarter, Zacks reports. Zero analysts have made estimates for Atara Biotherapeutics’ earnings, with estimates ranging from ($1.23) to ($1.06). Atara Biotherapeutics posted earnings of ($0.63) per share during the same quarter last year, which would suggest a negative year over year growth rate of 82.5%. The firm is expected to report its next earnings report on Thursday, March 8th.

According to Zacks, analysts expect that Atara Biotherapeutics will report full-year earnings of ($4.00) per share for the current year, with EPS estimates ranging from ($4.08) to ($3.91). For the next fiscal year, analysts forecast that the company will report earnings of ($4.62) per share, with EPS estimates ranging from ($4.97) to ($4.27). Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that follow Atara Biotherapeutics.

A number of equities research analysts recently commented on the company. BidaskClub upgraded Atara Biotherapeutics from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. ValuEngine upgraded Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Zacks Investment Research downgraded Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, February 6th. Cowen assumed coverage on Atara Biotherapeutics in a research report on Friday, January 26th. They issued an “outperform” rating on the stock. Finally, Canaccord Genuity reiterated a “positive” rating and issued a $70.00 target price (up from $47.00) on shares of Atara Biotherapeutics in a research report on Friday, January 19th. One research analyst has rated the stock with a sell rating, three have given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $30.60.

Atara Biotherapeutics (ATRA) traded up $3.30 during trading hours on Wednesday, hitting $48.35. The company had a trading volume of 1,427,669 shares, compared to its average volume of 1,256,386. The stock has a market capitalization of $1,480.00, a P/E ratio of -13.93 and a beta of 2.71. Atara Biotherapeutics has a 12 month low of $11.80 and a 12 month high of $49.90.

In other Atara Biotherapeutics news, CEO Isaac E. Ciechanover sold 2,200 shares of the business’s stock in a transaction that occurred on Thursday, December 28th. The stock was sold at an average price of $15.15, for a total transaction of $33,330.00. Following the sale, the chief executive officer now directly owns 743,675 shares of the company’s stock, valued at $11,266,676.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Isaac E. Ciechanover sold 4,400 shares of the business’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $14.25, for a total value of $62,700.00. The disclosure for this sale can be found here. Insiders have sold 279,098 shares of company stock worth $7,155,400 over the last three months. 16.20% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of ATRA. Dimensional Fund Advisors LP grew its stake in shares of Atara Biotherapeutics by 2.9% during the second quarter. Dimensional Fund Advisors LP now owns 21,718 shares of the biotechnology company’s stock valued at $304,000 after buying an additional 610 shares during the last quarter. Teachers Advisors LLC grew its stake in shares of Atara Biotherapeutics by 2.4% during the second quarter. Teachers Advisors LLC now owns 47,156 shares of the biotechnology company’s stock valued at $660,000 after buying an additional 1,110 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Atara Biotherapeutics by 7.2% during the second quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock valued at $285,000 after buying an additional 1,369 shares during the last quarter. Voya Investment Management LLC grew its stake in shares of Atara Biotherapeutics by 16.2% during the second quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock valued at $165,000 after buying an additional 1,651 shares during the last quarter. Finally, Alps Advisors Inc. grew its stake in shares of Atara Biotherapeutics by 12.7% during the fourth quarter. Alps Advisors Inc. now owns 33,904 shares of the biotechnology company’s stock valued at $614,000 after buying an additional 3,809 shares during the last quarter. 69.58% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Atara Biotherapeutics Inc (ATRA) Expected to Post Earnings of -$1.15 Per Share” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/14/atara-biotherapeutics-inc-atra-expected-to-post-earnings-of-1-15-per-share.html.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Get a free copy of the Zacks research report on Atara Biotherapeutics (ATRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply